Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer.

about

Omega-3 PUFA Loaded in Resveratrol-Based Solid Lipid Nanoparticles: Physicochemical Properties and Antineoplastic Activities in Human Colorectal Cancer Cells In Vitro.New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer.

P2860

Q49805224-84430B46-9A9D-4207-9D8E-9682DCAA1F0B Q55367746-F9DB1659-212F-4A4C-9B00-137501386FC7

P2860

Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer.

Item

http://www.wikidata.org/entity/Q38153444

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Molecularly targeted therapy: ...... in advanced colorectal cancer.

@en

type

Item

label

Molecularly targeted therapy: ...... in advanced colorectal cancer.

@en

prefLabel

Molecularly targeted therapy: ...... in advanced colorectal cancer.

@en

P1476

Molecularly targeted therapy: ...... in advanced colorectal cancer.

@en

P2093

Angela S Ribecco

http://www.w3.org/2001/XMLSchema#string

Claudio Marinozzi

http://www.w3.org/2001/XMLSchema#string

Greta Cipriani

http://www.w3.org/2001/XMLSchema#string

Luisa Fioretto

http://www.w3.org/2001/XMLSchema#string

Maria S Pino

http://www.w3.org/2001/XMLSchema#string

P2860

VEGF inhibition and renal thrombotic microangiopathy

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

The biology of VEGF and its receptors

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

P304

1181-1191

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/14737140.2013.837667

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24134420

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer.

about

P2860

P2860

Molecularly targeted therapy: toxicity and quality of life considerations in advanced colorectal cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921